The present disclosure provides formulations and methods for administration of dietary monensin to be fed to ruminants, including cattle. As described herein, monensin can provide beneficial effects of increasing dietary monensin concentration on milk yield and milk component yield, including milk fat yield, milk fat percentage, milk protein yield, and milk protein percentage.

The present disclosure provides formulations and methods for administration of dietary monensin to be fed to ruminants, including cattle. As described herein, monensin can provide beneficial effects of increasing dietary monensin concentration on milk yield and milk component yield, including milk fat yield, milk fat percentage, milk protein yield, and milk protein percentage.

Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.

##STR00001##

The disclosure discloses a composition containing melatonin as an effective ingredient, and its application in improving DHI production performance and improving milk quality. The composition containing melatonin as an effective ingredient according to the present disclosure can significantly reduce the somatic cell count in milk and improve milk quality. Under the conditions of different seasons, ages, and lactation periods, the administration of the composition containing melatonin as an active ingredient according to the present disclosure can significantly reduce the somatic cell score of cow milk (p<0.01), increase the protein content and lactose content in milk, and meanwhile reduce the fat content and urea nitrogen content in milk. In summary, the composition containing melatonin as an effective ingredient according to the present disclosure can improve the quality of milk and increase the efficiency of dairy cow breeding.

The disclosure discloses a composition containing melatonin as an effective ingredient, and its application in improving DHI production performance and improving milk quality. The composition containing melatonin as an effective ingredient according to the present disclosure can significantly reduce the somatic cell count in milk and improve milk quality. Under the conditions of different seasons, ages, and lactation periods, the administration of the composition containing melatonin as an active ingredient according to the present disclosure can significantly reduce the somatic cell score of cow milk (p<0.01), increase the protein content and lactose content in milk, and meanwhile reduce the fat content and urea nitrogen content in milk. In summary, the composition containing melatonin as an effective ingredient according to the present disclosure can improve the quality of milk and increase the efficiency of dairy cow breeding.

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: ##STR00001##
wherein R.sub.1a, R.sub.1b, R.sub.1c, R.sub.1d, R.sub.2, R.sub.2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.

The present invention is directed to the use of at least one SGLT-2 inhibitor in a non-human mammal, preferably ruminant, preferably for drying-off of a non-human mammal, preferably ruminant, as well as corresponding methods, such as improving and/or facilitating the drying-off of a non-human mammal, preferably ruminant, comprising administering to such non-human mammal, preferably ruminant, at least one SGLT-2 inhibitor.

The present invention is directed to the use of at least one SGLT-2 inhibitor in a non-human mammal, preferably ruminant, preferably for drying-off of a non-human mammal, preferably ruminant, as well as corresponding methods, such as improving and/or facilitating the drying-off of a non-human mammal, preferably ruminant, comprising administering to such non-human mammal, preferably ruminant, at least one SGLT-2 inhibitor.

Methods for treating triple negative breast cancer with an androgen receptor inhibitor are provided, as well as methods for screening for the likelihood of the effectiveness of such treatment.